Core Viewpoint - Longshen Rongfa's stock price has shown a significant increase this year, with a notable rise in trading volume and market capitalization, indicating positive investor sentiment and potential growth in the pharmaceutical sector [1][2]. Group 1: Stock Performance - As of December 3, Longshen Rongfa's stock price increased by 2.18% to 10.79 CNY per share, with a trading volume of 1.77 billion CNY and a turnover rate of 5.49%, resulting in a total market capitalization of 32.73 billion CNY [1]. - The stock has risen by 24.60% year-to-date, with a 3.06% increase over the last five trading days, 5.89% over the last 20 days, and 6.10% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Longshen Rongfa reported a revenue of 647 million CNY, a year-on-year decrease of 19.71%, while the net profit attributable to shareholders was 27.03 million CNY, reflecting a year-on-year growth of 9.13% [2]. - Cumulatively, the company has distributed dividends amounting to 42.64 million CNY since its A-share listing, with 24.27 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of November 28, the number of shareholders for Longshen Rongfa reached 27,800, an increase of 3.93% from the previous period, with an average of 10,874 circulating shares per shareholder, a decrease of 3.78% [2]. - Among the top ten circulating shareholders, Huatai-PineBridge's Zhongzheng Traditional Chinese Medicine ETF holds 1.33 million shares, an increase of 351,800 shares compared to the previous period [3].
陇神戎发涨2.18%，成交额1.77亿元，主力资金净流入709.74万元